title: The role of the CRH type 1 receptor in autonomic responses to corticotropin- releasing hormone in the rat.
abstract: The involvement of the corticotropin-releasing hormone (CRH) type 1 receptor in CRH-induced cardiac responses was studied in freely moving rats. Intracerebroventricular (icv) infusion of 2 microg CRH under resting conditions resulted in a significant increase in heart rate (HR), but did not significantly affect the PQ interval of the electrocardiogram. This effect involves sympathetic nervous system (SNS) activation, since CRH-treatment resulted in a marked increase in plasma norepinephrine (NE) and epinephrine (E), and sympathetic blockade by subcutaneously injected atenolol (1 mg/kg), a beta1-selective adrenergic antagonist, completely prevented the CRH-induced tachycardia. CRH infusion after sympathetic blockade resulted in an elongation of the PQ interval, indicating CRH-induced vagal activation. Gross locomotor activity (GA) was determined to study its possible indirect effects on cardiac activity. Although CRH induced a marked increase in GA, this effect followed the tachycardiac response, indicating that the HR response was not a consequence of increased locomotor activity, but was a direct effect of icv CRH. Treatment with CP-154,526 (icv, 10 or 25 microg), a selective CRH type 1 receptor antagonist, did not affect baseline HR, plasma NE and E, whereas it partially blocked the CRH-induced increase in HR, plasma NE and E levels. CP-154,526 treatment had no significant effects on baseline or CRH-induced changes in GA. These results indicate that CRH activates the sympathetic nervous system at least in part via the CRH type 1 receptor.
authors.affiliation: Rudolf Magnus Institute for Neurosciences, Department of Medical Pharmacology, Utrecht University, Utrecht, The Netherlands. Nijsen@med.uu.nl
authors.forename: M J
authors.initials: MJ
authors.lastname: Nijsen
authors.forename: G
authors.initials: G
authors.lastname: Croiset
authors.forename: R
authors.initials: R
authors.lastname: Stam
authors.forename: A
authors.initials: A
authors.lastname: Bruijnzeel
authors.forename: M
authors.initials: M
authors.lastname: Diamant
authors.forename: D
authors.initials: D
authors.lastname: de Wied
authors.forename: V M
authors.initials: VM
authors.lastname: Wiegant
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects* / Q000502:physiology*; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009490:Neurosecretory Systems / Q000187:drug effects / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018019:Receptors, Corticotropin-Releasing Hormone / Q000502:physiology*
chemical_list: D000319:Adrenergic beta-Antagonists; C101628:CP 154526; D011743:Pyrimidines; D011758:Pyrroles; D018019:Receptors, Corticotropin-Releasing Hormone; D001262:Atenolol; D003346:Corticotropin-Releasing Hormone